Last 12 months
Inside the activity.
7 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 7 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 28, 2026 20:30 UTC |
Fisk RyanCFO and CBO
|
GrantEmployee Stock Option (right to buy) · Derivative | 170,692 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0002151480-26-000004 · form4-09282026_040903.xml · derivative · entry 1 Fisk Ryan · CIK 0002151480 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,692 Underlying: Common Stock · 170,692 shares Expires 2036-09-23 F1 · derivative.exercise_date: 1/4th of the total shares vest and become exercisable on September 24, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| September 24, 2026 Filed Sep 28, 2026 20:30 UTC |
MacLeod Alan RobertChief Scientific Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 170,692 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0002154450-26-000004 · form4-09282026_040905.xml · derivative · entry 1 MacLeod Alan Robert · CIK 0002154450 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,692 Underlying: Common Stock · 170,692 shares Expires 2036-09-23 F1 · derivative.exercise_date: 1/4th of the total shares vest and become exercisable on September 24, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.